Renaissance Technologies
PSTX

Renaissance Technologies’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Renaissance Technologies’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-271,200
Closed -$2.6M – 3975
2024
Q4 		$2.6M Sell
271,200
-626,403
-70% -$3.27M ﹤0.01% 1875
2024
Q3 		$2.57M Buy
897,603
+42,703
+5% +$132K ﹤0.01% 1859
2024
Q2 		$2.5M Buy
854,900
+297,500
+53% +$814K ﹤0.01% 1733
2024
Q1 		$1.78M Buy
557,400
+27,300
+5% +$91K ﹤0.01% 2107
2023
Q4 		$1.78M Sell
530,100
-252,971
-32% -$652K ﹤0.01% 2028
2023
Q3 		$1.86M Buy
783,071
+243,047
+45% +$509K ﹤0.01% 1912
2023
Q2 		$950K Sell
540,024
-63,176
-10% -$161K ﹤0.01% 2495
2023
Q1 		$1.86M Buy
603,200
+406,900
+207% +$2.44M ﹤0.01% 2076
2022
Q4 		$1.04M Sell
196,300
-147,000
-43% -$672K ﹤0.01% 2513
2022
Q3 		$1.21M Sell
343,300
-36,800
-10% -$122K ﹤0.01% 2377
2022
Q2 		$981K Buy
380,100
+193,100
+103% +$537K ﹤0.01% 2738
2022
Q1 		$838K Buy
187,000
+153,400
+457% +$692K ﹤0.01% 2848
2021
Q4 		$229K Buy
33,600
+20,700
+160% +$141K ﹤0.01% 3462
2021
Q3 		$94K Buy
+12,900
New +$111K ﹤0.01% 3327

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies's PSTX Position: Q1 2025 in Review

Renaissance Technologies sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 271,200 shares — an estimated $2.6M sold.

Renaissance Technologies first reported a position in PSTX in Q3 2021 and held it in 14 quarters. The position peaked at $2.6M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Renaissance Technologies reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 271,200 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $2.6M.
  • Renaissance Technologies first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2021 and held it in 14 quarters.
  • Renaissance Technologies's Poseida Therapeutics, Inc. Common Stock position peaked at $2.6M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.